#### **An Roinn Sláinte**Department of Health



By e-mail only: emlsecretariat@who.int

April 8th, 2023

Dear colleagues,

On behalf of Ireland, I wish to input to the review of the WHO essential medicines list (EML) and the companion EML for children. The inclusion of fluoride varnishes, fluoride gels and fluoride mouth rinses as well as resin composites in the EML/EMLc is welcomed to enable prevention and management of dental caries. This builds on the previous additions to EML which included fluoride toothpastes, silver diamine fluoride and glass ionomers.

An estimated 70% of Ireland's population has access to fluoridated water via its public water supplies. Fluorides in this and all other forms have a valuable role to play, from a public health perspective, to reduce inequalities in oral health. Equally the availability of alternative non- mercury containing materials for restoration of teeth is supportive for the successful phase-down of dental amalgam required by the Minamata Convention on Mercury.

As Chief Dental Officer, Department of Health in Ireland, I commissioned a series of umbrella evidence reviews to inform the implementation of our policy issues in

- Smile agus Sláinte (The Irish National Oral Health Policy-2019), https://assets.gov.ie/9614/d1be290ee99743f8ba4c0ef9ac4cb401.pdf
- Ireland's Amalgam Phase Down Plan (2019), https://assets.gov.ie/19422/18299e4340394a51801dae1fb29d4ade.pdf

An umbrella review was completed initially in 2018 and updated in 2022. It relates to the **Management of Dental Caries.** 

https://www.hrb.ie/fileadmin/2. Plugin\_related\_files/Publications/2022 Publication files/2022 Evidence Centre/ Management of non-cavitated and cavitated caries 2022.pdf

The second, a sister umbrella review, is the **Prevention of Dental Caries.** This is awaiting peer review and so I have attached the slide presentation that was made available to us. I have asked my colleagues in the HRB, Dr Jean Long and Dr Lisa Murphy, to liaise with you directly once the final report on **Prevention of Dental Caries** is available. They have agreed to release the non-peer reviewed version in advance to support your process.

In addition, colleagues in the Department of Environment, Climate and Communications (DECC) supported by us in the Office of the Chief Dental Officer, Department of Health, commissioned primary research in this subject area. This research was to inform the phase down of amalgam with a focus on the impact of alternative materials on the environment as well as possible related health and safety issues.

#### An Roinn Sláinte

Department of Health

Bloc 1, Plaza Miseach, 50 - 58 Sráid Bhagóid Íochtarach, Baile Átha Cliath, D02 XW14

Block 1, Miesian Plaza, 50-58 Lower Baggot Street, D02 XW14

T +353 1 6354000 | info@health.gov.ie

www.health.gov.ie



Unfortunately, colleagues in the DECC are unavailable to comment presently but the publicly available links are available at <a href="https://www.epa.ie">https://www.epa.ie</a> and are included below.

https://www.epa.ie/our-services/monitoring--assessment/waste/chemicals/mercury/

https://www.epa.ie/publications/research/waste/research-307.php

https://www.epa.ie/publications/research/environment--health/research-417.php

My colleagues in DECC, may wish to comment further on return from leave.

I trust these submissions will contribute to the evidence review of the WHO essential medicines. On behalf of the Department of Health and colleagues in the Health Research Board, we would be happy to facilitate further information sharing and discussion if it is helpful.

Yours with kind regards,

Olympia Kawanagh.

Dympna A Kavanagh BDS MSc PhD DDPH FDS FDS(DPH)

Chief Dental Officer, Ireland Tel: 00353 (0) 876275390

#### An Roinn Sláinte

Department of Health

Bloc 1, Plaza Miseach, 50 - 58 Sráid Bhagóid Íochtarach, Baile Átha Cliath, D02 XW14

Block 1, Miesian Plaza, 50-58 Lower Baggot Street, D02 XW14

T +353 1 6354000 | info@health.gov.ie

www.health.gov.ie



# Primary prevention of dental caries

An overview of reviews


Lisa Murphy, Louise Farragher, Kayleigh Clements, Annette Burns, Mary Archibald, and Jean Long



Research. Evidence. Action.

#### **Purpose**

To provide evidence to assist with the development of clinical guidelines for Ireland on the prevention of caries using individual-based primary prevention interventions prior to the development of any dental decay/dental caries  Evidence-based practice is comprised of three equal components:







What is the evidence from systematic reviews regarding individual-based interventions to prevent caries in:

- Primary teeth
- Permanent teeth
- Mixed teeth





#### **PICO**

Population	People with some or all teeth that are caries free	
Intervention	One or more of 43 possible interventions	
Comparator	No treatment, a placebo, any alternative treatment/intervention	
Outcome	Primary and secondary outcomes	
Study Design	Systematic reviews of trials and/or prospective longitudinal cohort studies	









# Methods \_\_\_

1. Developing the protocol

6. Categorising

2. Searching

7. Grading the certainty of evidence

3. Screening

8. Summarising the reviews

4. Extraction

9. Synthesising the evidence

5. Quality assessing the reviews

10. Assessing the overlap



#### **Methods 1: Protocol**



Protocol registered on PROSPERO

• CRD42022353754



#### Primary prevention of dental caries: A protocol for an overview of reviews




15 June 2022

Lisa Murphy

Martin Keane


#### **Methods 2: Search**


- We searched:
  - 3 clinical databases
  - 11 systematic review resources
  - 3 search engines
  - 6 resources for open access/grey/preprint material
- January 2010 to mid-June 2022






#### **Methods 3: Screening**





#### **Methods 4: Extraction**

- JBI extraction form
- Structured extraction of data from each review
- Factors that may have affected the outcome(s)



#### **Methods 5: Quality assessment**

16-item AMSTAR 2

- 7 critical flaws, e.g.
  - Not preparing a protocol
  - No characteristics of primary studies
  - Included high risk of bias studies
  - Did not discussed heterogeneity

Score	Criteria	No. reviews
High	No critical flaw	0
	0 or 1 non-critical flaw	
Moderate	No critical flaw	4
	>1 non-critical flaw	
Low	1 critical flaw	7
Critically low	>1 critical flaw	57



## **Methods 6: Categorising**

Dentition








## **Methods 6: Categorising**

Intervention





#### Methods 7: Grading the certainty of evidence

GRADE algorithm



#### **Criteria to determine certainty**

Non-RCT designs

Inadequate randomisation

Inadequate blinding

Substantial heterogeneity

Inadequate sample size

AMSTAR 2 quality rating

#### **Methods 7: Grading the certainty of evidence**

GRADE	No. reviews
High	0
Moderate	8
Low	31
Very low*	29



#### Methods 8 and 9: Summarising and synthesising

Summarised the findings of individual reviews

• Narratively synthesised the findings from the same or similar interventions



#### **Methods 10: Overlap**

- Overlap of primary studies across systematic reviews
- Pieper et al. method known as corrected covered area



#### **Methods 10: Overlap**

Outcome

Primary outcomes: general epi measures	Primary outcomes: dentistry epi measures	Secondary outcomes	
Any general indicator of caries incidence on any part of the tooth		Plaque (e.g. visible plaque index) Elevated mutans streptococci levels	
<ul> <li>% of new carious lesions</li> <li>Mean no. teeth with new caries</li> <li>Cumulative survival rate</li> </ul>	D(E/M)FS / d(e/m)fs (or variation) RCI	Oral health quality of life Sealant retention Adverse effects (e.g. fluorosis)	

#### **Methods 10: Overlap**

• Results of overlap assessment

Corrected covered area	Overlap	Number
0 – 5%	Slight	4
6 – 10%	Moderate	1
11 – 14%	High	7
15% +	Very high	16



# Findings





# **Primary dentition**






#### **Categories of findings**


Singular interventions


Interventions delivered to pregnant women/mothers


Combined interventions











#### **Primary dentition** Topical other Systemic fluoride Topical fluoride Sealants Milk Resin Toothpaste Gels Supplements Chemotherapeutic (chlorhexidine) Varnishes Probiotics

#### **Primary dentition** Topical other Systemic fluoride Topical fluoride Sealants Milk Resin Toothpaste Gels Supplements Chemotherapeutic (chlorhexidine) Varnishes Probiotics

#### Systemic fluoride – milk

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	Overlap of primary studies
Yeung <i>et al</i> . (2015)	180-200ml fluoridated milk per day (2.5mg fluoride per litre)	Non-fluoridated milk	dmft; significantly lower (1 trial)	3 years	Very low	
Cagetti <i>et al</i> . (2012)	200ml fluoridated milk per day (2.5mg fluoride per litre)	Control (unspecified)	dmft; significantly lower (1 trial)	21 months	Very low	
	150ml fluoridated milk (2.5mg fluoride per litre)	Standard milk	dmfs; significantly lower (1 trial)			

No overlap

# Systemic fluoride - supplements

	Systemic nuonae – supplements						
Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	Overlap of primary studies	
Zhou <i>et al.</i> (2019)			Not usable				
Tubert-Jeannin <i>et al.</i> (2011)	Fluoride tablets (1mg or 0.5mg NaF)	No tablets	<pre>dmft; divergent findings (2 trials, narrative summary)</pre>	2 years	Low		
	Fluoride tablets (0.5mg NaF)	No tablets	<pre>dmfs; significantly lower (1 trial)</pre>	2 years	Very low		
	Fluoride tablets (1mg or 0.25mg NaF)	Topical fluoride	dmfs; no difference (2 pooled trials)	3 years	Low		
Chou et al. (2021)	Supplements	No supplements	dmft; significantly lower	1-3 years	Very low		

(4 trials, narrative synthesis)

(1 trial)

(same trial)

dmft; significantly lower

dmfs; significantly lower

dmfs: very high dmft: high

(unspecified)

Fluoride drops/chews

Fluoride drops/chews

(0.25mg fluoride)

(0.25mg fluoride)

No drops/chews

No drops/chews

#### **Primary dentition** Topical other Systemic fluoride Topical fluoride Sealants Resin Milk Toothpaste Gels Supplements Chemotherapeutic agents (chlorhexidine) Varnishes Probiotics

#### **Topical fluoride – toothpaste**

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	Overlap of primary studies
Walsh <i>et al</i> . (2019)	High fluoride toothpaste (1450 ppm)	Low fluoride toothpaste (440 ppm)	% developing new caries; significantly lower (1 trial)	5 years	Very low	
Santos <i>et al</i> . (2013)	High fluoride toothpaste (1000-1500 ppm)	Low fluoride toothpaste (<640 ppm)	% developing new caries; significantly lower (3 pooled trials)	2 years	Low	

% developing new caries: very high

## Topical fluoride – gel

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	Overlap of primary studies
Marinho <i>et al</i> . (2015)	Fluoride gel (varied)	Placebo/no treatment	d(e/m)fs; significantly lower (3 pooled trials)	3 years	Low	
	Fluoride gel (APF 5000 ppm)	Placebo	% not remaining caries free; significantly lower (one of 3 pooled trials)	1.5 years	Very low	

# Tonical fluoride - varnish

dmfs; significantly lower

dmfs; no difference (1

(5 trials, narrative synthesis)

trial)

2 years

2 years

	Topical Huoride – varilish						
Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence		
Smith <i>et al.</i> (2018)	No trials						
Marinho et al. (2013)	Fluoride varnish (varied)	No treatment or placebo varnish	d(e/m)fs; significantly lower (10 pooled trials)	3 years	Very low		
			d(e/m)ft; significantly lower (2 pooled trials)	3 years			
			% developing new caries; no difference (5 pooled trials)	Unspecified			

No treatment or oral

health education

No treatment

Carvalho et al. (2010)

Fluoride varnish (5% NaF

or 1% Difluorsilano)

Fluoride varnish (5%


NaF)

Low

Very low

**Overlap of primary** studies

d(e/m)fs: high overlap d(e/m)ft: no overlap % new caries: no overlap



iopical other chemicals – chemotherapeutic agents							
Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	Overlap of primary studies	
Smith <i>et al</i> . (2018)	No trials						
Walsh <i>et al</i> . (2015)	Chlorhexidine varnish (1% or 40%)	No treatment/placebo varnish	dmfs/t-molar; no difference (3 pooled trials)	2 years	Low		
James <i>et al</i> . (2010)	Chlorhexidine varnish	Placebo varnish	dmfs-molar; significantly	2 years	Very low		

lower (1 trial)

dmfs (1 trial)

dmft (1 trial) dmfs-molar (2 trials) defs (2 trials); significantly lower

dft; no difference (1 trial)

(4 trials, narrative summary)

1.5 years

2-3 years

Very low

Low

d(e/m)fs/t 1%: very high d(e/m)fs 40%: very high d(e/m)fs/t 1%: very high dmfs/t: 40% no overlap

Rethman et al. (2011)

Wang et al. (2017)

(40%)

(1%)

Chlorhexidine varnish

Chlorhexidine varnish or

gel (1% or 40%)

No treatment

varnish

No treatment/placebo

## 

Caries incidence: no

ds/dmfs/dmft: high

overlap

iopical other chemicals – problotics						
Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	Overlap of primary studies
Hao <i>et al</i> . (2021)	Slow-release tablets/pacifiers containing	Placebo tablets/pacifiers	Caries incidence; no difference (1 trial)	2 years and 4 years	Very low	

ds; significantly lower\*

dmfs/t; significantly

lower (7 pooled trials)

(1 trial)

1 year

6 months and 1 year

Very low

Low

Jorgensen et al. (2016)

Twetman and Jorgensen

(2021)

Bifidobacterium (100g

**Probiotic lozenges** 

Streptococcus-derived

containing three

Probiotics milk or

(Streptococcus/Lactobac illus/Bifidobacterium)

Placebo lozenges

Placebo

or 300g)

strains

tablets

# Topical other chemicals – xylitol

dmfs (dichotomous): no difference (1 trial)

dmfs & caries incidence; no difference (1 trial)

dmfs; no difference (1 trial)

dmfs; no difference (1 trial)

dmfs; no difference (1 trial)

% new caries; significantly lower (1 trial)

Overlap of primary studies

No. decayed: none dmfs: very high Caries incidence/% new caries: complete

1 year

2 years

1 vear

2-2.5 years

2-2.5 years

1 year

Very low

Very low

	ТОРТОС		on cirrious	<i>7</i> . y		
Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	(
Riley <i>et al.</i> (2015)	Xylitol syrup (8g/day)	Xylitol syrup (2.67g/day)	No. decayed teeth; significantly lower (1 trial)	1 year	Very low	
	Xylitol sucking tablets (0.48g-1g/day)	No sucking tablet	dmfs (continuous); no difference (1 trial)	2 years		
	Xylitol tablets (200-600mg/day)	Placebo tablets	dmfs (dichotomous); no difference (1 trial)	2 years		

Placebo wipes

Placebo wipes

Placebo gummies

Placebo wipes

Xylitol syrup (2.67g/day)

No tablets

No wipes

Xylitol wipes (4.2g/day)

Xylitol wipes (4.2g/day)

Xylitol wipes (4.2g/day)

Xylitol wipes (4.2g/day)

Xylitol gummies (7.8g/day)

Xylitol syrup (8g/day)

Xylitol tablets (0.5mg/day)

Chou et al. (2021)

Rethman *et al.* (2011)

Wang *et al.* (2017)

#### **Primary dentition** Topical other Systemic fluoride Topical fluoride Sealants Resin Milk Toothpaste Gels Supplements Chemotherapeutic agents (chlorhexidine) Varnishes Probiotics

# Sealants – resin

Follow-up

Outcome

measure(s)

Comparator

Review

Intervention

**Certainty of** 

evidence

**Overlap of primary** 

incidence: very high

studies

Ramamurthy <i>et al</i> . (2022)	Auto-polymerised resin- based sealant	Polymerised resin-based sealant	Risk of developing ≥ 1 new carious lesions; no difference (1 trial)	2-3 years	Very low	
Lam <i>et al</i> . (2020)	Resin-based sealant	Glass-ionomer based sealant or resin- modified glass-ionomer based sealant	Caries incidence; no difference (1 trial)	1.5 years	Very low	
	Resin-based sealant	Fluoride-containing resin-based sealant (F- RBS) or amorphous calcium phosphate- resin-based sealant (ACP-RBS)	Caries incidence; no difference (1 trial)	2 years		
	Auto-polymerised resin- based sealant	Light-curing resin-based sealant	Caries incidence; no difference (1 trial)	2 years		
						Risk of new caries/caries

# **Summary**







- F milk
- F supplements
- F toothpaste
- F gels
- Probiotics




- F varnish
- Chlorhexidine





- Xylitol
- Resin-based sealant






















#### **Supervised toothbrushing**

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	Overlap of primary studies
Hujoel <i>et al</i> . (2018)	Supervised toothbrushing (varied frequency), non-fluoride toothpaste	Control (unspecified)	<b>DMFS</b> ; no difference (3 pooled trials)	2.5-3 years	Low	
Dos Santos <i>et al</i> . (2018)	Supervised toothbrushing (daily, school-based), non- fluoride toothpaste	No supervised toothbrushing	DMFS; no difference (1 trial)  DMFT; no difference (same trial)	21 months	Very low	



#### Systemic fluoride – supplements

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	Overlap of primary studies
Zhou <i>et al.</i> (2019)			Not usable			
Tubert-Jeannin <i>et al.</i> (2011)	Fluoride tablets	No tablets	<b>DMFS</b> ; significantly lower (3 pooled trials)	2-3 years	Low	
	Fluoride tablets	No tablets	<b>DMFT</b> ; significantly lower (3 pooled trials)	2-3 years		
	Fluoride supplements (tablets and lozenges)	Fluoride mouthrinse	<b>DMFS</b> ; no difference (4 pooled trials)	2-3 years		



#### **Topical fluoride – toothpaste**

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	Overlap of primary studies
Walsh <i>et al</i> . (2019)	Low fluoride (250 ppm fluoride)	Non-fluoride toothpaste	% developing new caries (immature dentition); no difference (2 pooled trials)	2 years	Low	
	High fluoride (1000- 1250)	Non-fluoride toothpaste	% developing new caries (immature dentition); no difference (7 pooled trials)	1-5 years	Low	
	High fluoride (1450- 1500)	Non-fluoride toothpaste	% developing new caries (immature dentition); significantly lower (1 trial)	3 years	Very low	
Zhang <i>et al</i> . (2020)	Fluoride toothpaste (1100-1500 ppm fluoride)	Control (unspecified)	D-Root and DF-Root; significant difference (network meta-analysis of 9 trials)	2 years	Very low	

#### Tonical fluorido - mouthringo

D-Root and DF-Root; significantly lower

(network meta-analysis

DMFS-root (DMFRS);

significantly lower (4

pooled trials)

2-3 years

of 9 trials)

	торг	Cai iiuo	ride – i	moutin	inse
Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence
Zhang <i>et al</i> . (2020)	Fluoride mouthrinse (0.05% NaF)	Control (unspecified)	<b>D-Root and DF-Root</b> ; no difference (network meta-analysis of 9 trials)	2 years	Very low

Placebo mouthrinse

Fluoride mouthrinse

Fluoride mouthrinse

(NaF, 225-900 ppm

fluoride)

(0.2% NaF)

Weirichs et al. (2015)

**Overlap of primary** studies

> D-Root / DF-Root / DMFRS: very high

Very low

## Topical fluoride – gel

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	Overlap of primary studies
Marinho et al. (2015)	Fluoride gel (varied)	Placebo gel/no gel	DMFS; significantly lower (25 pooled trials)	3 years	Low	
	Fluoride gel (2 groups; SnF2 2425 ppm fluoride and NaF 4500 ppm fluoride)	Placebo gel	% developing ≥ or more new caries in tooth surfaces; significantly lower (1 of 25 pooled trials)	1.5 and 3 years	Very low	
	Fluoride gel (2 groups; SnF2 2425 ppm fluoride and NaF 4500 ppm fluoride)	Placebo gel	Change in % not remaining caries free on tooth surfaces; significantly lower (same trial as above)	3 years	Very low	
	Fluoride gel (varied)	Placebo gel/no gel	DMFT; significantly lower (10 pooled trials)	3 years	Low	
Zhang <i>et al</i> . (2022)	Fluoride gel (1.2% APF)	Control (unspecified)	<b>D-Root and DF-Root</b> ; significantly lower (network meta-analysis of 9 trials)	2 years	Very low	

trial)

Root caries incidence; significant lower (1

2 years

Very low

Chan et al. (2022)

Fluoride gel (1.23% APF)

Placebo gel

#### Topical fluoride – solution

D-Root and DF-Root:

(network meta-analysis

DMFS-root (DMFRS);

significantly lower (1

DMFS-root (DMFRS);

significantly lower (1

Mean no. new root

carious lesions; significantly lower (3 pooled trials)

significantly lower

of 9 trials)

trial)

trial)

2 years

3 years

2 years

2 years

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	
Grandjean <i>et al</i> . (2021)	Silver diamine fluoride (concentration not reported)	Control (unspecified)	Mean no. new root carious surfaces; significantly lower (3 pooled trials)	2 years	Low	

Control (unspecified)

Control (unspecified),

Control (unspecified)

Control (unspecified)

chlorhexidine, and

fluoride varnish

Zhang et al. (2020)

Chan et al. (2022)

(2018)

Subbiah and Gopinathan

Silver diamine fluoride

Silver diamine fluoride

Silver diamine fluoride

Silver diamine fluoride

(38%, professional

application)

(38%)

(38%)

(38%)

Very low

Very low

Very low

Low

**Overlap of primary** 

Mean no. new root caries: complete overlap D-Root / DF-Root / DMFRS: high

studies

## Topical fluoride – varnish

**Overlap of primary** 

None, D-Root / DF-Root / DMFRS: very high

studies

Very low

Very low

	Topical Haoriae Vallisii					
Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	
Marinho et al. (2013)	Fluoride varnish (varied)	Placebo varnish/no treatment	<b>DMFS</b> ; significantly lower (13 pooled trials)	3 years	Very low	
			<b>DMFT</b> ; significantly lower (5 pooled trials)	3 years		
			% new caries; no			
			difference (5 pooled trials)	Not specified		
Zhang <i>et al.</i> (2020)	Fluoride varnish (5%	Control (unspecified)	D-Root and DF-Root;	2 years	Very low	
	NaF)		significantly lower (network meta-analysis			
1			(incertoric infecta arialysis			

Placebo varnish

No treatment

Water

Fluoride varnish (38%

silver diamine fluoride)

Fluoride varnish (5%

NaF)

Wierichs et al. (2015)

Chan et al. (2022)

of 9 trials)

DMFS-Root (DMFRS);

No. teeth with coronal

Root caries incidence;

significantly lower (1

trial)


caries; significantly lower (1 trial)

significantly lower (2 pooled trials)

2 years

1 year

3 years



#### **Topical other chemicals – chemotherapeutic agents**

ropical other chemicals chemotherapeatic agents							
Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	Overlap of primary studies	
Walsh <i>et al</i> . (2015)	Chlorhexidine varnish (10% or 40%)	No treatment/placebo product	<b>DMFS</b> ; no difference (2 pooled trials)	2.5-3 years	Low		
Wierichs <i>et al</i> . (2015)	Chlorhexidine varnish (1% or 10%)	Placebo varnish	DMFS-Root (DMFRS); significantly lower (3 pooled trials)	1-3 years	Very low		
James <i>et al</i> . (2010)	Chlorhexidine varnish (1%, 10% or 40%)	Placebo varnish, control (unspecified) or fluoride varnish	<b>DMFS</b> ; divergent findings (11 trials, narrative synthesis)	2-3 years	Very low		
Rethman et al. (2011)	Chlorhexidine varnish	Placebo varnish	RCI; significantly lower (1 trial)	1 year	Very low		
	Chlorhexidine mouthrinse (0.12% or 0.05%)	Placebo mouthrinse or control (unspecified)	DMFS and incidence rate; no difference (4 pooled trials)	2-5 years			
	Chlorhexidine gel (1%)	Placebo gel	<b>D(E)FS</b> ; divergent findings (4 trials, narrative summary)	1-3 years			

#### **Topical other chemicals – calcium phosphate agents**

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	Overlap of primary studies
Rethman <i>et al</i> . (2011)	Casein derivative with calcium phosphate containing mouthrinse	0.05% NaF mouthrinse	<b>DFS</b> ; no difference (1 trial)	1 year	Very low	
	Casein phosphopeptide toothpaste	Fluoride toothpaste	<b>DFS</b> ; no difference (1 trial)			
Singal <i>et al</i> . (2022)	CPP-ACP cream	No treatment or 5% fluoride varnish	<b>DMFT</b> ; significantly lower (1 trial)	1 year	Very low	
						No overlap

#### Topical other chemicals – xylitol

DMFS; no difference (1

**DMFS scores and 2-year** 

incidence of proximal

enamel carious lesions;
no difference (1 trial)

trial)

2 years

2 years

Very low

Very low

**Overlap of primary** 

studies

DMFS: very high

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence		
Riggs et al. (2019)	No trials						
Riley <i>et al</i> . (2015)	Xylitol lozenges (5g/day or 4.7g/day)	Control lozenges or no treatment	<b>DMFS</b> ; no difference (2 trials, narrative synthesis)	3-4 years	Very low		

Conventional care

varnish)

varnish

(including preventive

Oral health education +

application of fluoride

Rethman et al. (2011)

Antonio et al. (2011)


**Xylitol candies** 

42.2% Xylitol lozenges

(2.5g/day)

#### **Topical other chemicals – polyols**

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	Overlap of primary studies
Rethman <i>et al</i> . (2011)	Sucrose-free polyol chewing gum	No gum	DMFS; significantly lower (9 pooled trials); no difference when non- randomised trials removed	2-3.5 years	Very low	
Antonio <i>et al</i> . (2011)	49% xylitol/maltitol and 49% xylitol/polydextrose candy	Control (unspecified)	DMFS; lowest 3-year increment* (1 trial)	3 years	Very low	
						DMFS: very high



### Sealants – resin

DMFS; no difference (2

New carious lesions; no

New carious lesions;

significantly lower (7

New carious lesions:

Caries incidence; no

difference (4 pooled trials)

DFS; significantly lower (1

significantly lower (1 trial)

difference (2 pooled trials)

2-3 years

2 years

1 year

2-3 years

Low

Moderate

Very low

Very low

Very low

pooled trials)

pooled trials)

trial)

**Overlap of primary** 

Caries incidence/new carious lesions: slight DFS/DMFS: very high

studies

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence
Four reviews			Not usable		
Alsabek <i>et al.</i> (2021)	Hydrophilic resin-based sealant	Resin-based sealant	Caries incidence; no difference (5 pooled trials)	1 year	Low
Rashed <i>et al</i> . (2022)	Resin-based sealant	Fluoride varnish	Caries incidence; no difference (3 pooled trials)	2 years	Low

Fluoride varnish

Control (unspecified)

No sealant

No sealant

Fluoride varnish

Kashbour et al. (2020)

Ahovuo-Saloranta et al.

(2017)

CADTH (2016)

Li et al. (2020)

Resin-based sealant

Second-, third-, and

based sealants

based sealants

fourth-generation resin-

Auto-polymerised resin-

Resin-based sealant

Resin-based sealant

#### Sealants – glass-ionomer **Certainty of** Outcome measure(s) Follow-up

**Overlap of primary** 

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	evidence	studies
Kashbour <i>et al</i> . (2020)	Glass-ionomer sealant	Fluoride varnish	New carious lesions; "no overall difference" (3 trials, narrative synthesis)*	3 years	Low	
Ahovuo-Saloranta et al. (2017)	Glass-ionomer sealant	No sealant	<b>DFS</b> ; no difference (1 trial)	2 years	Very low	
	Glass-ionomer sealant	Resin-based sealant	Caries incidence; no difference (6 pooled trials)	1 year	Moderate	
	Low-viscosity glass-ionomer sealant	Resin-based sealant	Caries incidence; no difference (10 pooled trials)	2 years	Moderate	
	High-viscosity glass-ionomer sealant	Resin-based sealant	Caries incidence; no difference (2 pooled trials)	2 years	Moderate	
	Resin-modified glass-ionomer sealant	Resin-based sealant	Caries incidence; significant favouring the comparator (2 pooled trials)	2 years	Moderate	
	Glass-ionomer sealant	Resin-based sealant	Caries incidence; significant favouring the comparator (5 trials, narrative synthesis)	3-4 years	Moderate	
	Low-viscosity glass-ionomer sealant	Resin-based sealant	Caries incidence; no difference (2 trials, narrative synthesis)	3-4 years	Moderate	
	Low-viscosity glass-ionomer sealant	Second-generation resinbased sealant	Caries incidence; significantly lower (1 trial)	4 years	Very low	
	ART high-viscosity glass- ionomer sealant	Resin-composite sealant	Cumulative survival rate; significantly higher (1 trial)	4 years	Very low	

#### Sealants – glass-ionomer cont'd

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	Overlap of primary studies
Wright <i>et al.</i> (2016)	Glass-ionomer sealant	Resin-based sealant	Presence of new caries lesions; no difference (9 pooled trials)	2-3 years	Very low	
	Glass-ionomer sealant	Resin-modified glass- ionomer sealant	Presence of new caries lesions; no difference (1 trial)			
	Glass-ionomer sealant	Polyacid-modified resin sealant	Presence of new caries lesions; no difference (1 trial)			
CADTH (2016)	ART glass-ionomer cement	Supervised toothbrushing	Caries incidence; no difference (1 trial)	3 years	Very low	
						Caries incidence: moderate DFS: no overlap

# Sealants – combined

**DMFT**; significantly

Caries incidence and

DMFS; no difference (6

DMFS; no difference (3

lower (1 trial)

pooled trials)

pooled trials)

7 years

2-3 years

2 years

Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certaint evidence
Wright <i>et al</i> . (2016)	Sealant	No sealant	No. new caries lesions; significantly lower (6 pooled trials)	2-3 years	Very low
		Fluoride varnish	No. new caries lesions; significantly lower (2 pooled trials)		
CADTH (2016)	Sealant	No sealant	Caries prevention*; no effect (1 trial)	1 year	Very low

No sealant

Fluoride varnish

Akera et al. (2022)

Li et al. (2020)

Sealant

Sealant

cainty of Overlap of primary
lence studies
low

No. new caries/caries incidence: slight DMFS: no overlap DMFT: no overlap

Very low

Very low

## **Summary**







- F supplements
- F mouthrinse
- F gels
- F solution
- Polyols



- F toothpaste
- F varnish
- CHX
- Calcium phosphate
- Resin
- Glass-ionomer
- Sealants (combined)



- Supervised brushing
- Xylitol






















#### **Quantity of evidence**

- 68 systematic reviews
  - 68 single trial outcomes
    - 14 outcomes informed by only 2 trials
- Just in primary and permanent dentition
  - Mixed dentition
  - Combined interventions



#### **Certainty of evidence**

GRADE	No. reviews
High	0
Moderate	8
Low	31
Very low*	29



#### Reporting of reporting





# Topical other chemicals – xylitol

dmfs; no difference (1 trial)

dmfs; no difference (1 trial)

dmfs; no difference (1 trial)

dmfs & caries incidence; no difference (1 trial)

% new caries; significantly lower (1 trial)\*

2 years

1 vear

2-2.5 years

2-2.5 years

1 year

Very low

Very low

Overlap of primary studies

Topical oti			Circinicais	Ayiitoi		
Review	Intervention	Comparator	Outcome measure(s)	Follow-up	Certainty of evidence	
Riley et al. (2015)	Xylitol syrup (8g/day)	Xylitol syrup (2.67g/day)	No. decayed teeth, significantly lower (1 trial)	1 year	Very low	

Chou et al. (2021)

Wang et al. (2017)

Xylitol tablets (0.5mg/day)

Xylitol wipes (4.2g/day)

Xylitol wipes (4.2g/day)

Xylitol wipes (4.2g/day)

Xylitol gummies (7.8g/day)

No tablets

No wipes

Placebo wipes

Placebo gummies

Placebo wipes

### **Conclusions**





#### **Conclusions**

- More methodologically sound reviews are required
- Reporting standards vary widely and impact the validity of the findings
- Best evidence for fluoride-based interventions
- Lots of evidence gaps





# Primary prevention of dental caries

An overview of reviews

Lisa Murphy, Louise Farragher, Kayleigh Clements, Annette Burns, Mary Archibald, and Jean Long

